ClinicalTrials.gg
CompletedNCT04948333Updated Mar 18, 2026Results posted

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

A Phase 3 interventional study of ABL001 40mg BID and ABL001 80mg QD in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 48 sites in 16 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
199
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 8 open to participants now, 13 under way, 2 of them phase 3. asciminib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
6th of 21
199 · median 100
Started
2021
with 4 others
Phase 3
5 of 21
none open now
Registered
12th of 21
by date
Lead sponsor
12 of 21
Novartis Pharmaceuticals

Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 6th largest by enrollment, is one of 5 that started in 2021, is one of 5 in phase 3, and was the 12th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

8 of the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About asciminib

asciminib: first FDA approval 2021 (SCEMBLIX), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs).

Read the detailed description

This study consists of a screening period of up to 28 days, a treatment period of 144 weeks and a post-treatment safety follow-up period of 4 weeks.

Patients will receive asciminib as study treatment continuously for up to 144 weeks or until disease progression, treatment failure or intolerance to treatment. At treatment initiation, asciminib will be provided to all trial patients at a total daily dose of 80 mg. All patients will be randomly assigned 1:1 to 2 groups with 80 mg given either as 40 mg b.i.d. or 80 mg q.d., using IRT to avoid any selection bias.

In patients not achieving Major Molecular Responses (MMR) at 48 weeks or losing the response after the week 48 assessment up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation. In addition, there must not be any grade 3 or 4 toxicity while on therapy, or persistent grade 2 toxicity, possibly related to asciminib and unresponsive to optimal management.

The trial will enroll a total of approximately 186 patients:

  • 156 patients with CML-CP not in MMR at baseline who were treated with two or more TKIs and who were either resistant (ELN 2020 warning or failure) or intolerant to the last treatment will be enrolled. For this population, the primary endpoint for MMR at 48 weeks will be assessed.
  • Up to 30 additional patients intolerant only to their last TKI treatment and in MMR at baseline will also be enrolled. This patient population will not be part of primary endpoint analysis; however, all assessments will be done as with the 156 patients from the population of the primary endpoint analysis.
03

Conditions studied

  • Chronic Myelogenous Leukemia

Keywords

  • ABL001
  • Phase 3
  • tyrosine kinase inhibitor
  • Chronic myelogenous leukemia (CML)
  • chronic myeloid leukemia (CML)
  • chronic myelocytic leukemia (CML)
  • chronic granulocytic leukemia (CGL)
  • cancer of the white blood cells
  • clonal bone marrow stem cell disorder
  • proliferation of mature granulocytes
  • Treatment optimization
  • Asciminib
  • European Leukemia Network (ELN) Recommendations 2020
  • Major Molecular Response (MMR) rate at 48 weeks
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • Signed must be obtained prior to participation in the study
  • Male or female patients with a diagnosis of CML-CP ≥ 18 years of age
  • Treatment with a minimum of 2 or more prior TKIs (i.e. imatinib, nilotinib, dasatinib, bosutinib, radotinib or ponatinib)
  • Warning or failure (adapted from the 2020 ELN Recommendations) or intolerance to the most recent TKI therapy at the time of screening
  • (ECOG) performance status (PS) of 0, 1, or 2
  • Adequate end organ function (as per central laboratory tests)

Key Exclusion criteria:

  • Known presence of the BCR::ABL1 T315I mutation at any time prior to study entry
  • Known second chronic phase of CML after previous progression to AP/BC
  • Previous treatment with a hematopoietic stem-cell transplantation
  • Patient planning to undergo hematopoietic stem cell transplantation
  • Uncontrolled cardiac repolarization abnormality
  • Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
  • History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
  • Testing for surface antigen (HbsAg) and Hepatitis B core antibody (HBcAb / anti HBc) will be performed at screening. Patients with active Hepatitis B Virus (HBV) infection (hepatitis B surface antigen [HbsAg] positive) will be excluded

Other Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    ABL001

    Participants will be treated with 80 mg of ABL001 (40 mg BID or 80mg QD). In patients not achieving MMR at 48 weeks or losing the response after the week 48 assessment up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation.

    Drug: ABL001 40mg BID · Drug: ABL001 80mg QD · Drug: ABL001 200mg QD

Interventions

  • One tablet of 40 mg will be taken orally twice a day (BID)

    Also known as: asciminib

  • Two tablets of 40 mg will be taken orally once a day (QD)

    Also known as: asciminib

  • Five tablets of 40 mg will be taken orally once a day (QD)

    Also known as: asciminib

06

What researchers measure

Primary outcomes

  1. Major Molecular Response (MMR) Rate at Week 48 for All Patients With no Evidence of MMR at Baseline

    Major Molecular Response (MMR) is defined as a significant reduction in the level of BCR::ABL1 transcripts, which are the genetic markers of chronic myeloid leukemia (CML). Specifically, MMR is achieved when there is a ≥ 3.0 log reduction in BCR::ABL1 transcripts compared to a standardized baseline, which corresponds to a BCR::ABL1/ABL1 ratio of ≤ 0.1% on the international scale (IS). The Major Molecular Response (MMR) rate at Week 48 for all patients with no evidence of MMR at baseline refers to the percentage of patients who achieve MMR after 48 weeks of treatment, despite not having MMR at the start.

    Time frame: Week 48

Secondary outcomes

  1. MMR Rate at Week 12, 24, 36, 72, 96 and 144 for Patients With no MMR at Baseline

    The Major Molecular Response (MMR) rate at alternative time points (weeks 12, 24, 36, 72, 96 and 144) for all patients with no evidence of MMR at baseline refers to the percentage of patients who achieve MMR after those respective weeks of treatment, despite not having MMR at the start. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.

    Time frame: Week 12, 24, 36, 72, 96 and 144

  2. Major Molecular Response (MMR) Rate at Week 48 for Patients With MMR at Baseline

    The Major Molecular Response (MMR) rate at Week 48 for patients with MMR at baseline refers to the percentage of patients who maintain or achieve MMR after 48 weeks of treatment. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.

    Time frame: Week 48.

  3. Time to MMR for Subjects Without MMR at Baseline

    Time to MMR defined as the time from the date of randomization to the date of the first documented MMR. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.

    Time frame: From the date of enrollment to the date of first documented MMR, assessed up to 144 weeks

  4. Rate of BCR::ABL1 ≤ 10% for Subjects Without MMR at Baseline

    The rate of BCR::ABL1 ≤ 10% refers to the percentage of patients who achieve a BCR::ABL1 level of 10% or lower within the first 48 weeks of treatment.

    Time frame: Week 12, 24, 36 and 48

  5. Rate of BCR::ABL1 ≤ 1% for Subjects Without MMR at Baseline

    The rate of BCR::ABL1 ≤ 1% refers to the percentage of patients who achieve a BCR::ABL1 level of 1% or lower within the first 48 weeks of treatment.

    Time frame: Week 12, 24, 36 and 48.

  6. Deep Molecular Responses (MR4) Rate for Subjects Without MMR at Baseline

    Deep molecular responses (MR4) is defined as a ≥ 4 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.01% BCR::ABL1/ABL1 by the international scale (IS).

    Time frame: Week 12, 24, 36, 48, 72, 96 and 144.

  7. Deep Molecular Responses (MR4.5) Rate for Subjects Without MMR at Baseline

    Deep molecular responses (MR4.5) is defined as a ≥ 4.5 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.0032% BCR::ABL1/ABL1 by the international scale (IS).

    Time frame: Week 12, 24, 36, 48, 72, 96 and 144.

  8. Rate of Complete Cytogenetic Response (CCyR) for Subjects Without MMR at Baseline

    Cytogenetic Response is assessed based on the percentage of Philadelphia chromosome-positive (Ph+) metaphases in the bone marrow, with a review of at least 20 metaphases required. Complete Cytogenetic Response (CCyR) is defined as 0% Ph+ metaphases in the bone marrow.

    Time frame: Week 48 and end of treatment (up to 144 weeks)

  9. Occurrence of High-risk Additional Chromosomal Abnormalities (ACA) for Subjects Without MMR at Baseline

    High-risk additional chromosomal abnormalities (ACAs) are specific chromosomal abnormalities that are considered to increase the risk in Philadelphia chromosome-positive (Ph+) cells.

    Time frame: Up to 144 weeks

  10. Cumulative Molecular Response Rate of BCR::ABL1 ≤ 10% for Subjects Without MMR at Baseline

    The cumulative molecular response rate refers to the proportion of subjects achieving a BCR::ABL1 level of ≤ 10% on the international scale (IS) over a specified period.

    Time frame: From enrollment to end of treatment up to 144 weeks.

  11. Cumulative Molecular Response Rate of BCR::ABL1 ≤1% for Subjects Without MMR at Baseline

    The cumulative molecular response rate refers to the proportion of subjects achieving a BCR::ABL1 level of ≤ 1% on the international scale (IS) over a specified period.

    Time frame: From enrollment to end of treatment up to 144 weeks.

  12. Cumulative Molecular Response Rate of MMR for Subjects Without MMR at Baseline

    The cumulative molecular response rate refers to the proportion of subjects achieving MMR, defined as a BCR::ABL1 ratio of ≤ 0.1% on the international scale (IS), over a specified period.

    Time frame: From enrollment to end of treatment up to 144 weeks.

  13. Cumulative Molecular Response Rate of MR4 for Subjects Without MMR at Baseline

    The cumulative molecular response rate refers to the proportion of subjects achieving MR4, defined as a ≥ 4 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.01% BCR::ABL1/ABL1 by the international scale (IS), over a specified period.

    Time frame: From enrollment to end of treatment up to 144 weeks.

  14. Cumulative Molecular Response Rate of MR4.5 for Subjects Without MMR at Baseline

    The cumulative molecular response rate refers to the proportion of subjects achieving MR4.5, defined as a ≥ 4.5 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.0032% BCR::ABL1/ABL1 by the international scale (IS), over a specified period.

    Time frame: From enrollment to end of treatment up to 144 weeks.

  15. Duration of MMR

    Duration of MMR is defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to accelerated phase (AP) or blast crisis (BC), or CML-related death. The duration of MMR is analyzed for the subjects in FAS who achieved MMR at any time.

    Time frame: From the date of the first documented molecular response at MMR level to the date of first documented loss of the response level or death due to any cause, whichever occurs first, assessed up to 144 weeks.

  16. Duration of MR4 Without Loss of MMR

    Duration of MR4 without loss of MMR refers to the period during which a patient maintains a deep molecular response (MR4) without experiencing a loss of Major Molecular Response (MMR).

    Time frame: From the date of first documented MR4 without loss of MMR to the date of first documented loss of the response level or death due to any cause, whichever occurs first, assessed up to 144 weeks.

  17. Progression-Free Survival (PFS) for Subjects Without MMR at Baseline

    Progression-Free Survival (PFS) is defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause, assessed up to approximately 144 weeks. The time will be censored at the date of last study assessment (PCR, cytogenetic, hematologic or extramedullary) or last post-treatment follow-up for subjects without event. PFS (in months) is calculated as: (date of disease progression/death or censoring date - date of randomization +1)/30.4375.

    Time frame: Up to 144 weeks.

  18. Overall Survival (OS) for Subjects Without MMR at Baseline

    Overall Survival (OS) is defined as the time from treatment assignment to death due to any cause during study, assessed up to 144 weeks. Subjects who are alive at the time of the analysis data cutoff date will be censored at the date of last contact before the cut-off date. OS (in months) is calculated as: (date of death or censoring date - date of randomization + 1)/30.4375.

    Time frame: Up to 144 weeks.

  19. Time to Treatment Failure (TTF) for Subjects Without MMR at Baseline

    Time from treatment assignment to treatment failure is defined as BCR-ABL1\>10%, assessed up to 144 weeks. For subjects who have not reached treatment failure, their TTFs will be censored at the time of last study assessment (PCR, cytogenetic, hematologic or extramedullary) before the cut-off date. TTF (in months) is calculated as: (date of treatment failure or censoring date - date of randomization + 1)/30.4375.

    Time frame: Up to 144 weeks.

  20. Change in Symptom Burden and Interference From Baseline Over Time According to the MDASI-CML PRO Instrument

    The MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) is a 26 item self-administered questionnaire for adult CML patients. Twenty of the items measure the severity of disease-related symptoms (symptom burden) and are scored from 0 (not present) to 10 (as bad as you can imagine) and 6 items that measure symptom interference with daily life (interference) scored from 0 (did not interfere) to 10 (interfered completely). For symptom burden, total scores range from 0 to 200 and for interference range from 0 to 60, with higher scores indicates high impact on severity of chronic myeloid leukemia-related symptoms and on impact of these symptoms on daily functioning for the patient.

    Time frame: Week 4, 12, 24, 48, 72, 96, 120 and at end of treatment (up to 144 weeks).

07

Results

Posted Mar 27, 2025

Participant flow

The study is conducted globally across 16 countries.

Participant flow — Overall Study
MilestoneAsciminib 40 mg b.i.d. - Subjects Without MMR at BaselineAsciminib 80 mg q.d. - Subjects Without MMR at BaselineAsciminib 40 mg b.i.d. - Subjects With MMR at BaselineAsciminib 80 mg q.d. - Subjects With MMR at Baseline
Started85841416
Full analysis set (fas)858400
Full analysis set 2 (fas 2)001416
Safety set (saf)848400
Safety set 2 (saf 2)001416
Completed0000
Not completed85841416
Withdrew: Adverse event6402
Withdrew: Unsatisfactory therapeutic effect4300
Withdrew: Progressive disease1500
Withdrew: Physician decision2200
Withdrew: Failure to meet continuation criteria2100
Withdrew: Withdrawal by subject2001
Withdrew: Protocol violation0100
Withdrew: Treatment ongoing at the time of the data cut-off date 12-mar-202468681413

Outcome measures

PrimaryMajor Molecular Response (MMR) Rate at Week 48 for All Patients With no Evidence of MMR at Baseline

Major Molecular Response (MMR) is defined as a significant reduction in the level of BCR::ABL1 transcripts, which are the genetic markers of chronic myeloid leukemia (CML). Specifically, MMR is achieved when there is a ≥ 3.0 log reduction in BCR::ABL1 transcripts compared to a standardized baseline, which corresponds to a BCR::ABL1/ABL1 ratio of ≤ 0.1% on the international scale (IS). The Major Molecular Response (MMR) rate at Week 48 for all patients with no evidence of MMR at baseline refers to the percentage of patients who achieve MMR after 48 weeks of treatment, despite not having MMR at the start.

Time frame:
Week 48
Reported as:
Number · Percentage of responders
Major Molecular Response (MMR) Rate at Week 48 for All Patients With no Evidence of MMR at Baseline
Percentage of respondersAsciminib 40 mg b.i.d. - Subjects Without MMR at BaselineAsciminib 80 mg q.d. - Subjects Without MMR at Baseline
Major Molecular Response (MMR) Rate at Week 48 for All Patients With no Evidence of MMR at Baseline42.35 (31.70 to 53.55)34.52 (24.48 to 45.69)
SecondaryMMR Rate at Week 12, 24, 36, 72, 96 and 144 for Patients With no MMR at Baseline

The Major Molecular Response (MMR) rate at alternative time points (weeks 12, 24, 36, 72, 96 and 144) for all patients with no evidence of MMR at baseline refers to the percentage of patients who achieve MMR after those respective weeks of treatment, despite not having MMR at the start. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.

Time frame:
Week 12, 24, 36, 72, 96 and 144

Results for this outcome have not been posted.

SecondaryMajor Molecular Response (MMR) Rate at Week 48 for Patients With MMR at Baseline

The Major Molecular Response (MMR) rate at Week 48 for patients with MMR at baseline refers to the percentage of patients who maintain or achieve MMR after 48 weeks of treatment. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.

Time frame:
Week 48.
Reported as:
Number · Percentage of responders
Major Molecular Response (MMR) Rate at Week 48 for Patients With MMR at Baseline
Percentage of respondersAsciminib 40 mg b.i.d. - Subjects Without MMR at BaselineAsciminib 80 mg q.d. - Subjects Without MMR at Baseline
Major Molecular Response (MMR) Rate at Week 48 for Patients With MMR at Baseline100 (76.84 to 100.00)87.5 (61.65 to 98.45)
SecondaryTime to MMR for Subjects Without MMR at Baseline

Time to MMR defined as the time from the date of randomization to the date of the first documented MMR. MMR itself is defined as achieving a BCR::ABL1 ratio of ≤ 0.1%.

Time frame:
From the date of enrollment to the date of first documented MMR, assessed up to 144 weeks

Results for this outcome have not been posted.

SecondaryRate of BCR::ABL1 ≤ 10% for Subjects Without MMR at Baseline

The rate of BCR::ABL1 ≤ 10% refers to the percentage of patients who achieve a BCR::ABL1 level of 10% or lower within the first 48 weeks of treatment.

Time frame:
Week 12, 24, 36 and 48
Reported as:
Number · Percentage of BCR::ABL1 <= 10%
Rate of BCR::ABL1 ≤ 10% for Subjects Without MMR at Baseline
Percentage of BCR::ABL1 <= 10%Asciminib 40 mg b.i.d. - Subjects Without MMR at BaselineAsciminib 80 mg q.d. - Subjects Without MMR at Baseline
Week 1269.4 (58.47 to 78.95)81.0 (70.92 to 88.70)
Week 2472.9 (62.21 to 82.01)76.2 (65.65 to 84.81)
Week 3671.8 (60.96 to 81.00)82.1 (72.26 to 89.65)
Week 4871.8 (60.96 to 81.00)78.6 (68.26 to 86.78)
SecondaryRate of BCR::ABL1 ≤ 1% for Subjects Without MMR at Baseline

The rate of BCR::ABL1 ≤ 1% refers to the percentage of patients who achieve a BCR::ABL1 level of 1% or lower within the first 48 weeks of treatment.

Time frame:
Week 12, 24, 36 and 48.
Reported as:
Number · Percentage of BCR::ABL1 ≤ 1%
Rate of BCR::ABL1 ≤ 1% for Subjects Without MMR at Baseline
Percentage of BCR::ABL1 ≤ 1%Asciminib 40 mg b.i.d. - Subjects Without MMR at BaselineAsciminib 80 mg q.d. - Subjects Without MMR at Baseline
Week 1261.2 (49.99 to 71.56)53.6 (42.35 to 64.53)
Week 2464.7 (53.59 to 74.77)58.3 (47.06 to 69.00)
Week 3663.5 (52.38 to 73.71)64.3 (53.08 to 74.45)
Week 4864.7 (53.59 to 74.77)59.5 (48.25 to 70.10)
SecondaryDeep Molecular Responses (MR4) Rate for Subjects Without MMR at Baseline

Deep molecular responses (MR4) is defined as a ≥ 4 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.01% BCR::ABL1/ABL1 by the international scale (IS).

Time frame:
Week 12, 24, 36, 48, 72, 96 and 144.

Results for this outcome have not been posted.

SecondaryDeep Molecular Responses (MR4.5) Rate for Subjects Without MMR at Baseline

Deep molecular responses (MR4.5) is defined as a ≥ 4.5 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.0032% BCR::ABL1/ABL1 by the international scale (IS).

Time frame:
Week 12, 24, 36, 48, 72, 96 and 144.

Results for this outcome have not been posted.

SecondaryRate of Complete Cytogenetic Response (CCyR) for Subjects Without MMR at Baseline

Cytogenetic Response is assessed based on the percentage of Philadelphia chromosome-positive (Ph+) metaphases in the bone marrow, with a review of at least 20 metaphases required. Complete Cytogenetic Response (CCyR) is defined as 0% Ph+ metaphases in the bone marrow.

Time frame:
Week 48 and end of treatment (up to 144 weeks)

Results for this outcome have not been posted.

SecondaryOccurrence of High-risk Additional Chromosomal Abnormalities (ACA) for Subjects Without MMR at Baseline

High-risk additional chromosomal abnormalities (ACAs) are specific chromosomal abnormalities that are considered to increase the risk in Philadelphia chromosome-positive (Ph+) cells.

Time frame:
Up to 144 weeks

Results for this outcome have not been posted.

SecondaryCumulative Molecular Response Rate of BCR::ABL1 ≤ 10% for Subjects Without MMR at Baseline

The cumulative molecular response rate refers to the proportion of subjects achieving a BCR::ABL1 level of ≤ 10% on the international scale (IS) over a specified period.

Time frame:
From enrollment to end of treatment up to 144 weeks.

Results for this outcome have not been posted.

SecondaryCumulative Molecular Response Rate of BCR::ABL1 ≤1% for Subjects Without MMR at Baseline

The cumulative molecular response rate refers to the proportion of subjects achieving a BCR::ABL1 level of ≤ 1% on the international scale (IS) over a specified period.

Time frame:
From enrollment to end of treatment up to 144 weeks.

Results for this outcome have not been posted.

SecondaryCumulative Molecular Response Rate of MMR for Subjects Without MMR at Baseline

The cumulative molecular response rate refers to the proportion of subjects achieving MMR, defined as a BCR::ABL1 ratio of ≤ 0.1% on the international scale (IS), over a specified period.

Time frame:
From enrollment to end of treatment up to 144 weeks.

Results for this outcome have not been posted.

SecondaryCumulative Molecular Response Rate of MR4 for Subjects Without MMR at Baseline

The cumulative molecular response rate refers to the proportion of subjects achieving MR4, defined as a ≥ 4 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.01% BCR::ABL1/ABL1 by the international scale (IS), over a specified period.

Time frame:
From enrollment to end of treatment up to 144 weeks.

Results for this outcome have not been posted.

SecondaryCumulative Molecular Response Rate of MR4.5 for Subjects Without MMR at Baseline

The cumulative molecular response rate refers to the proportion of subjects achieving MR4.5, defined as a ≥ 4.5 log reduction in BCR::ABL1 transcripts compared to the standardized baseline, equivalent to 0.0032% BCR::ABL1/ABL1 by the international scale (IS), over a specified period.

Time frame:
From enrollment to end of treatment up to 144 weeks.

Results for this outcome have not been posted.

SecondaryDuration of MMR

Duration of MMR is defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to accelerated phase (AP) or blast crisis (BC), or CML-related death. The duration of MMR is analyzed for the subjects in FAS who achieved MMR at any time.

Time frame:
From the date of the first documented molecular response at MMR level to the date of first documented loss of the response level or death due to any cause, whichever occurs first, assessed up to 144 weeks.

Results for this outcome have not been posted.

SecondaryDuration of MR4 Without Loss of MMR

Duration of MR4 without loss of MMR refers to the period during which a patient maintains a deep molecular response (MR4) without experiencing a loss of Major Molecular Response (MMR).

Time frame:
From the date of first documented MR4 without loss of MMR to the date of first documented loss of the response level or death due to any cause, whichever occurs first, assessed up to 144 weeks.

Results for this outcome have not been posted.

SecondaryProgression-Free Survival (PFS) for Subjects Without MMR at Baseline

Progression-Free Survival (PFS) is defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause, assessed up to approximately 144 weeks. The time will be censored at the date of last study assessment (PCR, cytogenetic, hematologic or extramedullary) or last post-treatment follow-up for subjects without event. PFS (in months) is calculated as: (date of disease progression/death or censoring date - date of randomization +1)/30.4375.

Time frame:
Up to 144 weeks.

Results for this outcome have not been posted.

SecondaryOverall Survival (OS) for Subjects Without MMR at Baseline

Overall Survival (OS) is defined as the time from treatment assignment to death due to any cause during study, assessed up to 144 weeks. Subjects who are alive at the time of the analysis data cutoff date will be censored at the date of last contact before the cut-off date. OS (in months) is calculated as: (date of death or censoring date - date of randomization + 1)/30.4375.

Time frame:
Up to 144 weeks.

Results for this outcome have not been posted.

SecondaryTime to Treatment Failure (TTF) for Subjects Without MMR at Baseline

Time from treatment assignment to treatment failure is defined as BCR-ABL1\>10%, assessed up to 144 weeks. For subjects who have not reached treatment failure, their TTFs will be censored at the time of last study assessment (PCR, cytogenetic, hematologic or extramedullary) before the cut-off date. TTF (in months) is calculated as: (date of treatment failure or censoring date - date of randomization + 1)/30.4375.

Time frame:
Up to 144 weeks.

Results for this outcome have not been posted.

SecondaryChange in Symptom Burden and Interference From Baseline Over Time According to the MDASI-CML PRO Instrument

The MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) is a 26 item self-administered questionnaire for adult CML patients. Twenty of the items measure the severity of disease-related symptoms (symptom burden) and are scored from 0 (not present) to 10 (as bad as you can imagine) and 6 items that measure symptom interference with daily life (interference) scored from 0 (did not interfere) to 10 (interfered completely). For symptom burden, total scores range from 0 to 200 and for interference range from 0 to 60, with higher scores indicates high impact on severity of chronic myeloid leukemia-related symptoms and on impact of these symptoms on daily functioning for the patient.

Time frame:
Week 4, 12, 24, 48, 72, 96, 120 and at end of treatment (up to 144 weeks).

Results for this outcome have not been posted.

Adverse events

Collected over From first dose of study treatment up to the cut-off date for the Week 48 primary analysis (12-Mar-2024), approximately 29 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Asciminib 40 mg b.i.d. - Subjects Without MMR at Baseline0/85 (0%)9/84 (10.7%)67/84 (79.8%)
Asciminib 80 mg q.d. - Subjects Without MMR at Baseline1/84 (1.2%)9/84 (10.7%)67/84 (79.8%)
Asciminib 40 mg b.i.d. - Subjects With MMR at Baseline0/14 (0%)4/14 (28.6%)12/14 (85.7%)
Asciminib 80 mg q.d. - Subjects With MMR at Baseline0/16 (0%)5/16 (31.3%)15/16 (93.8%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventAsciminib 40 mg b.i.d. - Subjects Without MMR at BaselineAsciminib 80 mg q.d. - Subjects Without MMR at BaselineAsciminib 40 mg b.i.d. - Subjects With MMR at BaselineAsciminib 80 mg q.d. - Subjects With MMR at Baseline
Coronary artery diseaseCardiac disorders0/840/841/140/16
Blindness unilateralEye disorders0/840/841/140/16
Incisional herniaInjury, poisoning and procedural complications0/840/841/140/16
Lipase increasedInvestigations0/840/841/140/16
Angina pectorisCardiac disorders0/841/840/141/16
Pancreatitis acuteGastrointestinal disorders0/840/840/141/16
Dengue feverInfections and infestations0/840/840/141/16
HyperkalaemiaMetabolism and nutrition disorders0/840/840/141/16
Cervicobrachial syndromeNervous system disorders0/840/840/141/16
HypertriglyceridaemiaMetabolism and nutrition disorders0/842/840/140/16
Most frequent other events
Showing 10 of 111
Most frequent other events
EventAsciminib 40 mg b.i.d. - Subjects Without MMR at BaselineAsciminib 80 mg q.d. - Subjects Without MMR at BaselineAsciminib 40 mg b.i.d. - Subjects With MMR at BaselineAsciminib 80 mg q.d. - Subjects With MMR at Baseline
PruritusSkin and subcutaneous tissue disorders12/845/843/145/16
DiarrhoeaGastrointestinal disorders7/846/841/144/16
ArthralgiaMusculoskeletal and connective tissue disorders10/8413/843/144/16
MyalgiaMusculoskeletal and connective tissue disorders5/844/842/144/16
HeadacheNervous system disorders8/848/842/144/16
COVID-19Infections and infestations11/849/843/143/16
NauseaGastrointestinal disorders6/848/840/143/16
BronchitisInfections and infestations2/844/840/143/16
Abdominal painGastrointestinal disorders5/845/842/142/16
FatigueGeneral disorders3/8412/841/141/16

Baseline characteristics

Age, Customized
Age, Customized(Participants)Asciminib 40 mg b.i.d. - Subjects Without MMR at BaselineAsciminib 80 mg q.d. - Subjects Without MMR at BaselineAsciminib 40 mg b.i.d. - Subjects With MMR at BaselineAsciminib 80 mg q.d. - Subjects With MMR at BaselineTotal
18 - < 65 years6459911143
65 - < 75 years12194338
>=75 years961218
Sex: Female, Male
Sex: Female, Male(Participants)Asciminib 40 mg b.i.d. - Subjects Without MMR at BaselineAsciminib 80 mg q.d. - Subjects Without MMR at BaselineAsciminib 40 mg b.i.d. - Subjects With MMR at BaselineAsciminib 80 mg q.d. - Subjects With MMR at BaselineTotal
Female37276676
Male4857810123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Asciminib 40 mg b.i.d. - Subjects Without MMR at BaselineAsciminib 80 mg q.d. - Subjects Without MMR at BaselineAsciminib 40 mg b.i.d. - Subjects With MMR at BaselineAsciminib 80 mg q.d. - Subjects With MMR at BaselineTotal
American Indian or Alaska Native00000
Asian21212246
Native Hawaiian or Other Pacific Islander00000
Black or African American42006
White58601214144
More than one race10001
Unknown or Not Reported11002
08

Study locations

48 sites
  • Novartis Investigative Site
    CABA, Buenos Aires C1221ADC, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1114AAN, Argentina
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Linz, 4010, Austria
  • Novartis Investigative Site
    Vienna, 1140, Austria
  • Novartis Investigative Site
    Rio de Janeiro, Rio de Janeiro 20211-030, Brazil
  • Novartis Investigative Site
    São Paulo, 01227-200, Brazil
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Mannheim, Baden-Wurttemberg 68305, Germany
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Kiel, 24116, Germany
  • Novartis Investigative Site
    München, 80377, Germany
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Thessaloniki, 570 10, Greece
  • Novartis Investigative Site
    Monza, MB 20900, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Verona, VR 37134, Italy
  • Novartis Investigative Site
    George Town, Pulau Pinang 10450, Malaysia
  • Novartis Investigative Site
    Kota Kinabalu, Sabah 88586, Malaysia
  • Novartis Investigative Site
    Johor Bahru, 80100, Malaysia
  • Novartis Investigative Site
    Kuala Selangor, 68000, Malaysia
  • Novartis Investigative Site
    Khoudh, 123, Oman
  • Novartis Investigative Site
    Katowice, 40-519, Poland
  • Novartis Investigative Site
    Warsaw, 00-791, Poland
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Seoul, Korea 03080, South Korea
  • Novartis Investigative Site
    Seoul, 06351, South Korea
  • Novartis Investigative Site
    Taegu, 41944, South Korea
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    Bilbao, Bizkaia 48013, Spain
  • Novartis Investigative Site
    Santa Cruz, Santa Cruz De Tenerife 38009, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Leeds, West Yorkshire LS9 7TF, United Kingdom
  • Novartis Investigative Site
    Cambridge, CB2 0QQ, United Kingdom
  • Novartis Investigative Site
    London, SE1 9RT, United Kingdom
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
  • Novartis Investigative Site
    Hanoi, 100000, Vietnam
  • Novartis Investigative Site
    Ho Chi Minh City, 70000, Vietnam
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Mar 2024, 28 months.

Results were first posted in Mar 2025, 1 year after primary completion.

Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2021
First posted
Jul 1, 2021
StartActual
Oct 13, 2021
Primary completionActual
Mar 12, 2024
CompletionActual
Feb 25, 2026
Results first posted
Mar 27, 2025
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04948333
Responsible party
Sponsor
First posted
Jul 1, 2021
Start date
Oct 13, 2021
Primary completion
Mar 12, 2024
Completion
Feb 25, 2026
Results posted
Mar 27, 2025
Last update
Mar 18, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asciminib

Start the discussion